Sarepta Therapeutics annual gross margin
2016
2022
2023
2024
2025
Sarepta Therapeutics Gross Margin Growth & History (SRPT)
Sarepta Therapeutics's gross margin was 98.63% for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 98.63% | +10.10 pp |
| 2024 | 2024-12-31 | 88.53% | −6.94 pp |
| 2023 | 2023-12-31 | 95.47% | +1.48 pp |
| 2022 | 2022-12-31 | 93.99% | — |
| 2016 | 2016-12-31 | 97.60% | — |
Sarepta Therapeutics quarterly gross margin
Q4.16
Q1.17
Q2.17
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 76.63% | +6.36 pp |
| Q1 2026 | 2026-03-31 | 188.20% | +110.70 pp |
| Q4 2025 | 2025-12-31 | −6.57% | −83.40 pp |
| Q3 2025 | 2025-09-30 | 59.25% | −19.41 pp |
| Q2 2025 | 2025-06-30 | 70.27% | −17.38 pp |
| Q1 2025 | 2025-03-31 | 77.50% | −8.43 pp |
| Q4 2024 | 2024-12-31 | 76.83% | — |
| Q3 2024 | 2024-09-30 | 78.67% | — |
| Q2 2024 | 2024-06-30 | 87.65% | — |
| Q1 2024 | 2024-03-31 | 85.94% | — |
| Q2 2017 | 2017-06-30 | 98.47% | — |
| Q1 2017 | 2017-03-31 | 98.46% | — |
| Q4 2016 | 2016-12-31 | 97.60% | — |
Sarepta Therapeutics gross margin trends
Between the periods ended 2016-12-31 and 2025-12-31, Sarepta Therapeutics's gross margin increased from 97.60% to 98.63%, a change of +1.03 percentage points. The latest reported quarter, Q2 2026, shows 76.63%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...